Results 41 to 50 of about 13,550 (188)
Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
Access Microbiology, 2020 Pseudomonas aeruginosa is an important bacterial cause of a variety of infections and is associated with high morbidity and mortality. Infections caused by this bacterium are becoming more difficult to treat due to increasing resistance to many of the available antibiotics. Ceftolozane–tazobactam and ceftazidime–avibactam are two new
Jeremy Jacobs +2 more
openaire +2 more sources
mSphere, 2022 Ceftazidime-avibactam is an effective antibiotic combination of a β-lactam and a β-lactamase inhibitor against Klebsiella pneumoniae-carbapenemase (KPC)-producing Enterobacterales.
Siquan Shen +7 more
doaj +1 more source
İstanbul Tıp Fakültesi Dergisi, 2022 Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul +5 more
doaj +1 more source
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms [PDF]
Antimicrobial Agents and Chemotherapy, 2017 ABSTRACT Ceftazidime-avibactam (CAZ-AVI) is a recently approved β-lactam–β-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients with such infections were included in the CAZ-AVI clinical trials, and clinical experience is lacking.
Temkin, Elizabeth +20 more
openaire +10 more sources
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
mSphere, 2019 Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich +5 more
doaj +1 more source
Microbiology Spectrum, 2022 A novel Klebsiella pneumoniae carbapenemase (KPC) variant, KPC-93, was identified in two Klebsiella pneumoniae clinical isolates from a patient from China treated with ceftazidime-avibactam.
Yuchen Wu +7 more
doaj +1 more source
KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae
Antimicrobial Agents and Chemotherapy, 2021 Carbapenem-resistant Enterobacterales , such as Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae , represent a major threat to public health due to their rapid spread.
Jacqueline Findlay +3 more
openaire +3 more sources
mSphere, 2018 A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpression of AcrAB-
Mariana Castanheira +5 more
doaj +1 more source
Pathogens, 2021 We report the emergence of an isolate belonging to the sequence type (ST)131-Escherichia coli high-risk clone with ceftazidime-avibactam resistance recovered from a patient with bacteremia in 2019.
Marta Hernández-García +6 more
doaj +1 more source
Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam [PDF]
, 2022 We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system ...
Avison, Matthew B +2 more
core +1 more source